Cliff Bentz
Cliff Bentz (R-OR) bought $1K-$15K of $AMGN (Amgen Inc. - Common Stock) on Jun 6, 2025, part of 2 transactions in this filing.
HillSignal flagged 1 timing concern on this filing — trades that line up closely with related legislative or contract activity.
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
1 flagThese flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
4 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Treat and Reduce Obesity Act of 2025
The Treat and Reduce Obesity Act of 2025 would mandate Medicare Part D coverage of GLP-1 obesity drugs, unlocking a massive new payer market of ~27 million beneficiaries. $NVO and $LLY are the two direct beneficiaries. The bill is in early-stage committee referral with 22 bipartisan cosponsors; no companion bill has passed the House yet. Real market data shows $NVO gaining 15.56% over 30 days vs $LLY's +0.7%, suggesting the market may be overweighting Novo's near-term Medicare exposure given its larger U.S. obesity market share.
ABC Safe Drug Act
The ABC Safe Drug Act (S. 1407) is in early legislative stages, having been referred to the Senate Finance Committee. It phases in restrictions on federal health programs purchasing drugs with Chinese active ingredients by 2030 and provides temporary tax incentives for domestic pharmaceutical manufacturing. Major pharma stocks ($PFE, $MRK, $JNJ, $LLY, $AMGN) show mixed but broadly negative 7-day changes, reflecting sector headwinds rather than this nascent bill. No market-moving impact is imminent.
Biosimilar Red Tape Elimination Act
The Biosimilar Red Tape Elimination Act (HR5526) would remove FDA interchangeability study requirements, speeding market entry for $VTRS and $TEVA biosimilars. Market data shows $VTRS +11.55% and $TEVA +17.73% over 30 days, consistent with investors pricing in this regulatory catalyst. Innovators $AMGN (-2.11% 30-day), $JNJ (-5.95%), and $BIIB (+4.18%) face structural margin pressure as pharmacy-level substitution becomes automatic upon biosimilar approval.
Small Biotech Innovation Act
The Small Biotech Innovation Act (HR3731) is an early-stage bill that would exempt R&D-intensive small biotech manufacturers (≤5 qualifying drugs) from Medicare drug price negotiations starting in 2029. The bill is in committee with no floor action, and no market reaction is evident from provided data. The legislative path is long and uncertain — this is a structural watch item, not a trading catalyst.
Other Filings by Cliff Bentz
Free — no credit card
Get the next Bentz trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.